SCHEMBL19316715

SCHEMBL19316715

Cc1cc(CN2CCN(C)CC2)cc(NC(=O)Nc2cc(-c3ccc4nc(N)ncc4c3)n(C)n2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NTRK1 P04629 4/20 0.43
▸ NTRK3 Q16288 3/20 0.43
▸ NTRK2 Q16620 3/20 0.43
▸ ABL1 P00519 4/20 0.41
▸ ABL2 P42684 1/20 0.39
▸ GSK3B P49841 3/20 0.39
▸ DYRK1A Q13627 3/20 0.39
▸ KDR P35968 4/20 0.39
▸ TEK Q02763 2/20 0.39
▸ LCK P06239 2/20 0.39
▸ JAK3 P52333 1/20 0.39
▸ MAPK14 Q16539 1/20 0.39
▸ KIT P10721 6/20 0.39
▸ FLT3 P36888 2/20 0.38
▸ CSF1R P07333 2/20 0.38
▸ DDR1 Q08345 1/20 0.38
▸ DDR2 Q16832 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19316714 0.91 FLT3 (0.46) NTRK1ABL1ABL2GSK3BDYRK1A
SCHEMBL19316721 0.89 DDR2 (0.48) NTRK1NTRK3NTRK2ABL1ABL2
SCHEMBL29614760 0.83 ABL1 (0.60) ABL1ABL2KDRMAPK14KIT
SCHEMBL19307227 0.83 ABL1 (0.60) ABL1ABL2KDRMAPK14KIT
SCHEMBL19316717 0.79 KDR (0.49) NTRK1NTRK3NTRK2ABL1ABL2
SCHEMBL20214560 0.76 KDR (0.46) NTRK1NTRK3NTRK2ABL1KDR
SCHEMBL20214661 0.76 ABL1 (0.46) ABL1ABL2MAPK14KITSRC
SCHEMBL19317711 0.76 ABL1 (0.53) NTRK1NTRK3NTRK2ABL1ABL2
SCHEMBL20227801 0.75 ABL1 (0.51) ABL1ABL2KDRTEKLCK
SCHEMBL19316719 0.75 ABL1 (0.55) ABL1ABL2KDRLCKMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220160705-A1 METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES CORNELL UNIVERSITY 2022-05-26 — — US disclosed
US-20210238167-A1 SMALL MOLECULE IRE1-ALPHA INHIBITORS CORNELL UNIVERSITY 2021-08-05 — — US disclosed
US-10988461-B2 Small molecule IRE1-α inhibitors CORNELL UNIVERSITY (US) 2021-04-27 — — US disclosed
US-20190016706-A1 SMALL MOLECULE IRE1-ALPHA INHIBITORS CORNELL UNIVERSITY 2019-01-17 — — US disclosed
US-20170253590-A1 SMALL MOLECULE IRE1-ALPHA INHIBITORS CORNELL UNIVERSITY 2017-09-07 — — US disclosed
US-20170253590-A1 SMALL MOLECULE IRE1-ALPHA INHIBITORS CORNELL UNIVERSITY 2017-09-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190016706-A1 SMALL MOLECULE IRE1-ALPHA INHIBITORS XBP1, ERN1, ERN2 NTRK1 4480/4885NTRK3 4059/4885NTRK2 4730/4885
US-20170253590-A1 SMALL MOLECULE IRE1-ALPHA INHIBITORS XBP1, ERN1, ERN2 NTRK1 4480/4885NTRK3 4059/4885NTRK2 4730/4885
US-20220160705-A1 METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES PTGES, PTGS1, PTGES2 NTRK1 4371/4885NTRK3 4544/4885NTRK2 3051/4885
US-10988461-B2 Small molecule IRE1-α inhibitors XBP1, ERN1, ERN2 NTRK1 4421/4885NTRK3 3992/4885NTRK2 4723/4885
US-20210238167-A1 SMALL MOLECULE IRE1-ALPHA INHIBITORS XBP1, ERN1, ERN2 NTRK1 4480/4885NTRK3 4059/4885NTRK2 4730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback